Why the study?
The study aimed to investigate the contribution of Epac1, a PKA-independent cAMP effector, to the response of cardiac myofilaments to beta-AR stimulation.
Population
Transgenic mice specifically overexpressing Epac1 in the heart and WT mice
Comparison
Epac1TG vs NTG mice and WT mice treated with 8CPT-AM vs control mice
Design
Animal experimental study
Follow-up
1 week
Authors
Loading...
Epac1 may accelerate HF under β-stimulation; hypothesis-generating for inhibition strategies pending human validation.
Epac1 activation increases the energetic cost of cardiac contraction and exacerbates the development of heart failure under chronic β-adrenergic stimulation in a mouse model.
Ohnuki et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: